CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Ipilimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02009397
NCT02009397Phase 2Completed
CompareCT.gov

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

University of Louisville·interventional·Posted Dec 12, 2013·Updated Nov 22, 2021

In Brief

A Phase 2 clinical trial evaluating Ipilimumab and GM-CSF for Metastatic Melanoma. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body. This study will also demostrate how safe the combined drugs are when used to treat patients with Stage 3 or Stage 4 melanoma (metastatic melanoma), which cannot be removed by surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Melanoma
CountriesUnited States
CollaboratorsJames Graham Brown Cancer Center

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 12, 2013
Enrollment StartFeb 1, 2012
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 12.6 years ago

Interventions

Ipilimumabdrug

GM-CSFdrug